| 摘要 |
<p>The present invention relates to the use of Volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia(AML) comprising administering a high dose of Volasertib in combination with fludarabine, cytarabine and Granulocyte colony-stimulating factor(GCSF) or in combination with fludarabine, cytarabine, GCSF and a daunorubicin citrate liposome injection.</p> |
